PortalPublikationenImmunohistochemical analysis of Bcl-2, nuclear S100A4, MITF ...

Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification

Standard

Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification. / Jurmeister, Philipp; Bockmayr, Michael; Treese, Christoph; Stein, Ulrike; Lenze, Dido; Jöhrens, Korinna; Friedling, Franziska; Dietel, Manfred; Klauschen, Frederick; Marsch, Wolfgang; Fiedler, Eckhard; von Laffert, Maximilian.

in: J DTSCH DERMATOL GES, Jahrgang 17, Nr. 8, 08.2019, S. 800-808.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Jurmeister, P, Bockmayr, M, Treese, C, Stein, U, Lenze, D, Jöhrens, K, Friedling, F, Dietel, M, Klauschen, F, Marsch, W, Fiedler, E & von Laffert, M 2019, 'Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification', J DTSCH DERMATOL GES, Jg. 17, Nr. 8, S. 800-808. https://doi.org/10.1111/ddg.13917

APA

Jurmeister, P., Bockmayr, M., Treese, C., Stein, U., Lenze, D., Jöhrens, K., Friedling, F., Dietel, M., Klauschen, F., Marsch, W., Fiedler, E., & von Laffert, M. (2019). Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification. J DTSCH DERMATOL GES, 17(8), 800-808. https://doi.org/10.1111/ddg.13917

Vancouver

Jurmeister P, Bockmayr M, Treese C, Stein U, Lenze D, Jöhrens K et al. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification. J DTSCH DERMATOL GES. 2019 Aug;17(8):800-808. https://doi.org/10.1111/ddg.13917

Bibtex

@article{ad3aab9414604ebeacccfcc4077f4442,
title = "Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification",
abstract = "BACKGROUND AND OBJECTIVES: Overall survival (OS) in patients with early-stage malignant melanoma differs. To date, there are no established prognostic markers. We aimed to contribute to a better understanding of potential prognostic immunohistochemical markers for risk stratification.PATIENTS AND METHODS: 161 surgically resected early-stage malignant melanomas (stage pT1 and pT2) were analyzed for expression of 20 different proteins using immunohistochemistry. The results were correlated with OS. The cohort was randomly split into a discovery and a validation cohort.RESULTS: High Bcl-2 expression, high nuclear S100A4 expression as well as a Ki67 proliferation index of ≥ 20 % were associated with shorter OS. Strong MITF immunoreactivity was a predictor for favorable prognosis. A combination of these four markers resulted in a multi-marker score with significant prognostic value in multivariate survival analysis (HR: 3.704; 95 % CI 1.484 to 9.246; p = 0.005). Furthermore, the score was able to differentiate a low-risk group with excellent OS rates (five-year survival rate: 100 %), an intermediate-risk group (five-year survival rate: 81.8 %) and a high-risk group (five-year survival rate: 52.6 %). The prognostic value was confirmed within the validation cohort.CONCLUSIONS: Combined immunohistochemical analysis of Bcl-2, nuclear S100A4, Ki67 and MITF could contribute to better risk stratification of early-stage malignant melanoma patients.",
author = "Philipp Jurmeister and Michael Bockmayr and Christoph Treese and Ulrike Stein and Dido Lenze and Korinna J{\"o}hrens and Franziska Friedling and Manfred Dietel and Frederick Klauschen and Wolfgang Marsch and Eckhard Fiedler and {von Laffert}, Maximilian",
note = "{\textcopyright} 2019 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.",
year = "2019",
month = aug,
doi = "10.1111/ddg.13917",
language = "English",
volume = "17",
pages = "800--808",
journal = "J DTSCH DERMATOL GES",
issn = "1610-0379",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification

AU - Jurmeister, Philipp

AU - Bockmayr, Michael

AU - Treese, Christoph

AU - Stein, Ulrike

AU - Lenze, Dido

AU - Jöhrens, Korinna

AU - Friedling, Franziska

AU - Dietel, Manfred

AU - Klauschen, Frederick

AU - Marsch, Wolfgang

AU - Fiedler, Eckhard

AU - von Laffert, Maximilian

N1 - © 2019 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.

PY - 2019/8

Y1 - 2019/8

N2 - BACKGROUND AND OBJECTIVES: Overall survival (OS) in patients with early-stage malignant melanoma differs. To date, there are no established prognostic markers. We aimed to contribute to a better understanding of potential prognostic immunohistochemical markers for risk stratification.PATIENTS AND METHODS: 161 surgically resected early-stage malignant melanomas (stage pT1 and pT2) were analyzed for expression of 20 different proteins using immunohistochemistry. The results were correlated with OS. The cohort was randomly split into a discovery and a validation cohort.RESULTS: High Bcl-2 expression, high nuclear S100A4 expression as well as a Ki67 proliferation index of ≥ 20 % were associated with shorter OS. Strong MITF immunoreactivity was a predictor for favorable prognosis. A combination of these four markers resulted in a multi-marker score with significant prognostic value in multivariate survival analysis (HR: 3.704; 95 % CI 1.484 to 9.246; p = 0.005). Furthermore, the score was able to differentiate a low-risk group with excellent OS rates (five-year survival rate: 100 %), an intermediate-risk group (five-year survival rate: 81.8 %) and a high-risk group (five-year survival rate: 52.6 %). The prognostic value was confirmed within the validation cohort.CONCLUSIONS: Combined immunohistochemical analysis of Bcl-2, nuclear S100A4, Ki67 and MITF could contribute to better risk stratification of early-stage malignant melanoma patients.

AB - BACKGROUND AND OBJECTIVES: Overall survival (OS) in patients with early-stage malignant melanoma differs. To date, there are no established prognostic markers. We aimed to contribute to a better understanding of potential prognostic immunohistochemical markers for risk stratification.PATIENTS AND METHODS: 161 surgically resected early-stage malignant melanomas (stage pT1 and pT2) were analyzed for expression of 20 different proteins using immunohistochemistry. The results were correlated with OS. The cohort was randomly split into a discovery and a validation cohort.RESULTS: High Bcl-2 expression, high nuclear S100A4 expression as well as a Ki67 proliferation index of ≥ 20 % were associated with shorter OS. Strong MITF immunoreactivity was a predictor for favorable prognosis. A combination of these four markers resulted in a multi-marker score with significant prognostic value in multivariate survival analysis (HR: 3.704; 95 % CI 1.484 to 9.246; p = 0.005). Furthermore, the score was able to differentiate a low-risk group with excellent OS rates (five-year survival rate: 100 %), an intermediate-risk group (five-year survival rate: 81.8 %) and a high-risk group (five-year survival rate: 52.6 %). The prognostic value was confirmed within the validation cohort.CONCLUSIONS: Combined immunohistochemical analysis of Bcl-2, nuclear S100A4, Ki67 and MITF could contribute to better risk stratification of early-stage malignant melanoma patients.

U2 - 10.1111/ddg.13917

DO - 10.1111/ddg.13917

M3 - SCORING: Journal article

C2 - 31437373

VL - 17

SP - 800

EP - 808

JO - J DTSCH DERMATOL GES

JF - J DTSCH DERMATOL GES

SN - 1610-0379

IS - 8

ER -